GeoVax Labs (GOVX) EBIAT (2016 - 2025)
GeoVax Labs (GOVX) has disclosed EBIAT for 16 consecutive years, with -$6.3 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 8.66% to -$6.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$25.3 million, a 4.06% decrease, with the full-year FY2024 number at -$25.0 million, up 3.75% from a year prior.
- EBIAT was -$6.3 million for Q3 2025 at GeoVax Labs, down from -$5.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$1.3 million in Q2 2021 to a low of -$13.7 million in Q4 2021.
- A 5-year average of -$5.3 million and a median of -$5.4 million in 2025 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 928.27% in 2021, then skyrocketed 60.83% in 2022.
- GeoVax Labs' EBIAT stood at -$13.7 million in 2021, then surged by 60.83% to -$5.4 million in 2022, then plummeted by 41.02% to -$7.6 million in 2023, then dropped by 8.83% to -$8.3 million in 2024, then increased by 23.52% to -$6.3 million in 2025.
- Per Business Quant, the three most recent readings for GOVX's EBIAT are -$6.3 million (Q3 2025), -$5.4 million (Q2 2025), and -$5.4 million (Q1 2025).